Assembly Biosciences (ASMB) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kamada (KMDA) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 14.7% versus a loss of 42.4%. Over five years, KMDA leads with a +22.7% price change compared with -21.3% for ASMB. Assembly Biosciences is the larger company by market cap ($454.4 million vs $446.8 million), about 1.0 times the size.
On valuation, Kamada trades at a lower trailing P/E (20.4x vs 29.6x for Assembly Biosciences). Kamada pays a dividend yielding 7.24%, while Assembly Biosciences does not currently pay one. Kamada converts more of its revenue into profit, with a net margin of 11.2% versus -8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | KMDA |
|---|---|---|
| Share price | $22.19 | $7.74 |
| Market cap | $454.39M | $446.85M |
| 1-day change | -1.38% | -1.15% |
| YTD return | -34.75% | +9.63% |
| 1-year return | -42.36% | +14.67% |
| 5-year return | -21.31% | +22.66% |
| P/E ratio (TTM) | 29.59 | 20.37 |
| Forward P/E | — | 13.34 |
| EPS (TTM) | $0.75 | $0.38 |
| Dividend yield | 0.00% | 7.24% |
| Annual dividend | $0.00 | $0.56 |
| Revenue (latest FY) | $72.30M | $180.46M |
| Revenue growth (YoY) | +153.52% | +12.12% |
| Net income (latest FY) | $-6.12M | $20.20M |
| Gross margin | — | 42.34% |
| Operating margin | -16.76% | 14.54% |
| Net margin | -8.47% | 11.19% |
| 52-week high | $39.65 | $9.35 |
| 52-week low | $19.20 | $6.63 |
| Distance from 52-week high | -44.04% | -17.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.73% | +77.65% |
| Average volume | 309.38K | 121.87K |
| Shares outstanding | 20.48M | 57.73M |
| Employees | 73 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed ASMB by 57.0 percentage points over the past year.
- Assembly Biosciences trades at a higher earnings multiple (29.6x vs 20.4x trailing P/E).
- Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
- Kamada is more profitable, keeping 11.2 cents of every revenue dollar as net income versus -8.5 cents for Assembly Biosciences.
- Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs +12.12%).
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
ASMB vs KMDA FAQ
Which is bigger, Assembly Biosciences or Kamada?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $454.39M compared with $446.85M for Kamada (KMDA).
Which stock has performed better over the past year, ASMB or KMDA?
KMDA returned +14.67% over the past 12 months, compared with -42.36% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASMB or KMDA?
KMDA has the lower trailing P/E at 20.4, versus 29.6 for ASMB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Assembly Biosciences or Kamada?
Kamada pays a dividend yielding 7.24%, while Assembly Biosciences does not currently pay a regular dividend.
Are Assembly Biosciences and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.